Amgen (AMGN) Tops Q3 EPS by 57c, Reves Beat; Raises Outlook

Amgen (NASDAQ: AMGN) reported Q3 EPS of $4.37, $0.57 better than the analyst estimate of $3.80. Revenue for the quarter came in at $6.4 billion versus the consensus estimate of $6.35 billion.

GUIDANCE:

Amgen sees FY2020 EPS of $15.80-$16.15, versus the consensus of $15.77. Amgen sees FY2020 revenue of $25.1-25.5 billion, versus the consensus of $25.41 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Traws Pharma (TRAW) Tops Q2 EPS by 27c